Pharmacoeconomic Assessment of Certolizumab Pegol in Adults With Axial Spondyloarthritis in Mexico

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1118
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Certolizumab Pegol in the Treatment of Axial Spondyloarthritis

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2015English

Cost-Effectiveness of Certolizumab Pegol in the Treatment of Active Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis in Romania

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

CERTOLIZUMAB PEGOL IN CHOHN'S DISEASE (Review)

Koloproktologia
2016English

Photoallergic Drug Eruption Caused by Certolizumab Pegol

Acta Dermato-Venereologica
DermatologyMedicine
2016English

Certolizumab Pegol for the Treatment of Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2011English

Axial Spondyloarthritis

2020English

Certolizumab Pegol in the Treatment of Takayasu Arteritis: The First Experience and Prospects

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2018English

PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis From a Brazilian Private Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy